Across TCGA pan-cancer cohorts, FRG2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FRG2 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher FRG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FRG2 expression acts as an unfavorable survival marker.
STAD and LIHC are the cancer types where FRG2 Mutation most reproducibly stratifies survival.